SCHEMBL23701624

SCHEMBL23701624

CC(C)OC(=O)NCCc1nnc(-c2ccccc2Nc2ccc(C(F)(F)F)cc2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.42
DDX3X O00571 1/20 0.41
TP53 P04637 1/20 0.37
FLT1 P17948 3/20 0.37
KDR P35968 3/20 0.37
BRD4 O60885 1/20 0.36
CTSV O60911 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
THRB P10828 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701542 0.91 ABCG2 (0.43) ABCG2DDX3XTP53FLT1KDR
SCHEMBL23701617 0.91 ABCG2 (0.46) ABCG2DDX3XTP53FLT1KDR
SCHEMBL22571358 0.88 HTT (0.46) ABCG2SMN1; SMN2KDM4EALDH1A1CYP1A2
SCHEMBL23701557 0.88 DDX3X (0.43) ABCG2DDX3XTP53FLT1KDR
SCHEMBL22556452 0.86 DDX3X (0.43) ABCG2DDX3XTP53FLT1KDR
SCHEMBL23701608 0.85 DDX3X (0.46) ABCG2DDX3XTP53FLT1KDR
SCHEMBL22556548 0.83 FLT1 (0.41) ABCG2DDX3XTP53FLT1KDR
SCHEMBL30463765 0.83 FLT1 (0.41) ABCG2DDX3XTP53FLT1KDR
SCHEMBL22556459 0.83 DDX3X (0.41) ABCG2DDX3XTP53FLT1KDR
SCHEMBL25530115 0.82 NPSR1 (0.50) ABCG2DDX3XTP53SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 ABCG2 2985/4885DDX3X 611/4885TP53 4/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 ABCG2 2985/4885DDX3X 611/4885TP53 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.